^
    Back
    Association details:
    Biomarker:KEAP1 mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:AiRuiKa (camrelizumab) (PD1 inhibitor) +
    AiTan (rivoceranib) (VEGFR-2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Efficacy and biomarker analysis of camrelizumab in combination with apatinib in patients with advanced non-squamous NSCLC previously treated with chemotherapy

    Published date:
    12/15/2020
    Excerpt:
    ...105 chemotherapy-pretreated patients with non-squamous NSCLC were enrolled and received apatinib 250 mg (recommended phase 2 dose) and camrelizumab….Efficacy of combination therapy was evident across all PD-L1 and tumor mutation burden subgroups, and appeared to be improved in patients with STK11/KEAP1 mutation (mutant vs . wild-type, ORR: 42.9% vs 28.1%; 1-year survival rate: 85.1% vs. 53.1%).
    DOI:
    10.1158/1078-0432.CCR-20-3136